AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05478278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
Study NCT05866081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveys
Description: All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes.
Study NCT05866081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes.
Study NCT04729296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
Study NCT04729296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Drug
Study NCT05478278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: The positive comparator used in this study is a 400 mg moxifloxacin tablet.
Study NCT05478278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micro-Crystalline Cellulose
Description: The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
Study NCT06296680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: The patients in the intervention group received Reiki to the seven chakra regions and additional areas with pain for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
Study NCT06296680 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki
Description: The patients in the placebo group received Sham Reiki to the seven chakra regions for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
Study NCT06296680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Relaxation Exercise
Description: PRE group patients received PRE for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
Study NCT05632393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
Study NCT06052592 — intervention group
Intervention type: OTHER
Intervention: Milk
Description: Newborns will be fed with breast milk, formula milk or postbiotic formula milk
Study NCT06571435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Posterior Shoulder Endurance Test
Description: The modified closed kinetic chain upper extremity stability test is reliable and is performed in an individualized manner by placing the hands on the floor at shoulder level. The evaluation process is the same as the original test; the total number of touches in 15 seconds is noted by lifting one hand, touching the other and placing it back. A total of 3 measurements are taken with a 45-second rest interval. The endurance capacity of the muscle group is an important factor for sports performance as it requires specific sports movements repeated in a certain period of time.~For posterior shoulder endurance test participants will lie with their face down. While the shoulder is hanging from the stretcher, individuals will be asked to lift the dumble calculated with the weight appropriate for their weight to 90 degrees abduction in accordance with the 60 bpm metronome. Their duration in seconds will be noted. 1 measurement will be made with each arm.
Study NCT05126303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-035
Description: Concentrate for Solution for Infusion
Study NCT05126303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concentrate for Solution for Infusion
Study NCT04723719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIESTA
Description: SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
Study NCT04723719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual for ADHD
Description: Participants continue their treatment as usual for ADHD.
Study NCT04723719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual for ADHD
Description: Participants continue their treatment as usual for ADHD.
Study NCT05612945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training group (HIIT)
Description: Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland).
Study NCT05612945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity training group (LowMod group)
Description: Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland).
Study NCT05790876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSO2 therapy
Description: SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
Study NCT05616442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: Mast cell stabilizer
Study NCT05616442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Dietary supplement
Study NCT05577741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory virtual reality pod (SENSIKS©)
Description: Six sessions of 20 minutes of mindfulness.
Study NCT05577741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bike (Vélo-cognitif®)
Description: Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
Study NCT05577741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard of care treatment
Study NCT05577741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard of care treatment
Study NCT06407011 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The CON group did not have any intervention but usual care.
Study NCT06407011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish massage prior circuit breathing training group (SBT)
Description: Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
Study NCT06407011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit breathing training group (CBT)
Description: Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
Study NCT05923723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIBNUTRITION
Description: The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant).
Study NCT05923723 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
Study NCT04883463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural stimulation
Description: Epidural electrical stimulation implant weekly sessions for 21 months.
Study NCT05821257 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the arm swing during gait
Description: Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
Study NCT05821257 — intervention group
Intervention type: OTHER
Intervention: Functional Tests
Description: To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
Study NCT01321294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic anti-reflux surgery
Study NCT04870112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 antibody
Study NCT04870112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy
Study NCT04870112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT06261918 — intervention group
Intervention type: PROCEDURE
Intervention: Influence of metabolic syndrome on the achievement of pathological complete response
Description: The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
Study NCT04450173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT04450173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT04450173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04835480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OrsHSA
Description: OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
Study NCT04835480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSA
Description: Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
Study NCT06097182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-biotic (Colonic-Delivery capsule)
Description: 250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
Study NCT06097182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post-biotic (Regular Administration capsule)
Description: 250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
Study NCT06097182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
Study NCT06097182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
Study NCT06613269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT
Description: 68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104.
Study NCT06613269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
Study NCT06613269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.
Study NCT06613269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
Study NCT06615947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic gait training
Description: RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.
Study NCT06615947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tRHB
Description: Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions.
Study NCT06616363 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires to be competed
Description: * The Pain Coping Questionnaire short form~* Functional Disability Inventory (FDI), the primary clinical outcome measure.~* COMPASS-31 and orthostatic hypotension modified for POTS.~* The Pain Response Inventory (PRI)PROMIS Depression~* GAD-7 for anxiety~* Varni/Thompson Pediatric Pain Questionnaire~* Child and Parent Reports of Post-Traumatic Symptoms (CROPS/PROPS)~* Pain Catastrophizing Scale (PCS-C)~* Detailed account of natural history and evolution of POTS and COPCs through MEDYSA (facilitates the assessment of specific syndromic diagnoses based on published criteria, rather than organ-based classification of symptoms)
Study NCT06616363 — intervention group
Intervention type: BEHAVIORAL
Intervention: Provide list of medication and lifetime events
Description: Participants will provide a list of all medications taken at each visit time, lifetime history of infections, traumas, and other significant life events.
Study NCT06616363 — intervention group
Intervention type: BEHAVIORAL
Intervention: Use phone App to record new life events
Description: Subjects will also record new life events, minor traumas, entrance into a flare and menses in Ilumivu's EMA (Ecological Momentary Assessment) phone App
Study NCT06616363 — intervention group
Intervention type: DEVICE
Intervention: Will wear an activity monitor
Description: Participants will have an activity monitor loaned for the duration of the study to track their physical activity.
Study NCT06616363 — intervention group
Intervention type: OTHER
Intervention: Periodic 24-hour urine sodium check
Description: POTS patients will have a periodic 24-hour urine sodium check to determine compliance to intake of salt.
Study NCT06097182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
Study NCT05825781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: i.v.
Study NCT04870112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy
Study NCT05202782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given IV
Study NCT05202782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05202782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05202782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study NCT05825781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta®
Description: i.v.
Study NCT04537650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Study (VFSS)
Description: A standardized dynamic radiographic examination of oropharyngeal swallowing
Study NCT06548048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement containing plant derived phenolics
Description: Dietary supplement containing plant derived phenolics
Study NCT06548048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystaline cellulose
Description: Microcrystaline cellulose (MCC)
Study NCT04778566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cologuard test
Description: Cologuard is a stool-DNA screening test for detecting colon cancer
Study NCT05042505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
Study NCT05042505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
Study NCT05294302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSCCIP/eSCCIP-SP
Description: eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.